We are currently accepting inquiries for our human clinical trials in India.

An ongoing clinical trial in India is currently evaluating the efficacy of RadioGel® treatment and is accepting international patients who are willing to travel to Bangalore, India. This trial aims to provide innovative treatment options for individuals with solid, non-metastatic tumors. Patients with inoperable tumors may also be eligible for participation.

Eligibility Criteria: 

• Must have a solid cancerous tumor. 
• Tumors should not have metastasized. 
• Patients with inoperable tumors are encouraged to apply
• The Phase II segment of this study focuses on treating cancerous nodes throughout the body, collecting critical data on the efficacy of RadioGel® across multiple cancer types.

Bangalore, India, is a leading hub for medical advancements in cancer treatment, driven by cutting-edge research, top-tier hospitals, and advanced technology. The city is home to renowned institutions like Kidwai Memorial Institute of Oncology, HCG Cancer Centre, and Narayana Health, which utilize state-of-the-art robotic surgeries, precision oncology, and AI-driven diagnostics. Bangalore’s biotech ecosystem fosters innovation in personalized medicine, immunotherapy, and genomic research, making it a global destination for advanced cancer care. With strong collaborations between research institutions, startups, and healthcare providers, the city continues to push the boundaries of cancer treatment and patient care.